Longitudinal Observational Study Of Chinese With NAFLD/NASH

Sponsor
Humanity and Health Research Centre (Other)
Overall Status
Recruiting
CT.gov ID
NCT03151473
Collaborator
(none)
20,000
1
124.7
160.3

Study Details

Study Description

Brief Summary

This is a 10-year, longitudinal, observational study of patients with NAFLD/NASH designed to specifically address important clinical questions that remain incompletely answered from registration trials. In addition to the study database, the biospecimen repository will also be included so that translational studies of genomics and biomarkers of response may be performed.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Non-alcoholic fatty liver disease (NAFLD) is an excess accumulation of fat in the liver cells. It is associated with obesity, high blood pressure, high cholesterol, and diabetes. Some people with NAFLD only have excess fat in the liver. However, other people may develop a worse form of NAFLD with liver injury and scarring. This form, called non-alcoholic steatohepatitis (NASH), can lead to liver failure, liver cancer, and death. Not much is known about why some people develop NASH and others do not.

    This study aims to determine and elucidate, through the cooperative effort of a multidisciplinary and multicenter group of collaborators, the etiology, natural history, diagnosis, treatment, and prevention of NAFLD, and in particular its more severe form of NASH and its complications in Chinese subjects.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    20000 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Prospective Cohort Assessing The Prevalence And Progress Of Non-Alcoholic Fatty Liver Disease (NAFLD)/Non-Alcoholic Steatohepatitis (NASH) In Chinese Subjects
    Actual Study Start Date :
    May 8, 2017
    Anticipated Primary Completion Date :
    May 31, 2027
    Anticipated Study Completion Date :
    Sep 30, 2027

    Outcome Measures

    Primary Outcome Measures

    1. Prevalence of NAFL/NASH in Chinese [up to 10 years]

      Determine the prevalence of NAFLD/NASH in military beneficiaries ages 18 or above. This will be determined by the % of subjects determined to have NAFLD/NASH in Chinese subjects.

    Secondary Outcome Measures

    1. Live imaging analysis [up to 10 years]

      Transient elastography (FibroScan) and/or MR elastography will provide a measurement of liver stiffness. The liver stiffness metrics will be tabulated for each of the three time points and assessed for change.

    2. Exploration, identification and validation of the circulating biomarkers for prediction and diagnosis of NAFL/NASH in Chinese [up to 10 years]

      Cytokeratin-18 (CK-18), fibrosis-4 (FIB-4), leptin, adiponectin, TNF-alpha, PAI-1, IL-6, MCP-1, retinoids and other potential biomarkers will be determined and analysed.

    3. Liver histology analysis [up to 10 years]

      Liver histology (derived from central reading of liver biopsy at entry, standard of care biopsy done during screening or follow-up) will be examined and scored.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Males or females aged 18 and older;

    • Adults being managed or treated for NAFL or NASH;

    • Be able to communicate meaningfully with the Investigator and be legally competent to provide written informed consent.

    Exclusion Criteria:
    • Incompetent to understand and/or sign the informed consent;

    • Ethanol consumption exceeding more than 14 standard beverages per week for males and more than 7 standard beverages per week for female;

    • Causes for secondary hepatic fat accumulation such as significant alcohol consumption, medications, Wilson's disease, viral infections, starvation or parenteral nutrition, among others, and conditions associated with microvesicular steatosis

    • Diagnosis of liver cirrhosis and/or hepatocellular carcinoma;

    • Diagnosis of chronic inflammatory disease (i.e. inflammatory bowel disease, rheumatoid arthritis, inflammatory lung disease, severe infectious diseases), other than NAFL/NASH.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Humanity and Health Medical Centre Hong Kong Hong Kong 00852

    Sponsors and Collaborators

    • Humanity and Health Research Centre

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Humanity and Health Research Centre
    ClinicalTrials.gov Identifier:
    NCT03151473
    Other Study ID Numbers:
    • H&H_NAFLD/NASH study_1
    First Posted:
    May 12, 2017
    Last Update Posted:
    Aug 30, 2021
    Last Verified:
    Aug 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 30, 2021